Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]
Tvardi Therapeutics, Inc. (TVRD)
Company Research
Source: Yahoo! Finance
biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in New York City, on April 14 th About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled, proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma ( NCT05440708 ) and TTI-109 in healthy volunteers. To learn more, pl
Show less
Read more
Impact Snapshot
Event Time:
TVRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVRD alerts
High impacting Tvardi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVRD
News
- Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.MarketBeat
- Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumGlobeNewswire
- Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Tvardi Therapeutics (TVRD) had its price target lowered by Piper Sandler from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
TVRD
Earnings
- 3/31/26 - Miss
TVRD
Sec Filings
- 4/1/26 - Form S-8
- 4/1/26 - Form POS
- 4/1/26 - Form 424B3
- TVRD's page on the SEC website